BR112020020741A2 - Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável. - Google Patents

Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável. Download PDF

Info

Publication number
BR112020020741A2
BR112020020741A2 BR112020020741-1A BR112020020741A BR112020020741A2 BR 112020020741 A2 BR112020020741 A2 BR 112020020741A2 BR 112020020741 A BR112020020741 A BR 112020020741A BR 112020020741 A2 BR112020020741 A2 BR 112020020741A2
Authority
BR
Brazil
Prior art keywords
antibody
formulation
stable
vedolizumab
fact
Prior art date
Application number
BR112020020741-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Murali JAYARAMAN
Anuja Chandrasekar
Original Assignee
Dr. Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68164052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112020020741(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr. Reddy's Laboratories Limited filed Critical Dr. Reddy's Laboratories Limited
Publication of BR112020020741A2 publication Critical patent/BR112020020741A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112020020741-1A 2018-04-10 2019-04-10 Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável. BR112020020741A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841013645 2018-04-10
IN201841013645 2018-04-10
PCT/IN2019/050291 WO2019198099A1 (en) 2018-04-10 2019-04-10 Stable antibody formulation

Publications (1)

Publication Number Publication Date
BR112020020741A2 true BR112020020741A2 (pt) 2021-01-19

Family

ID=68164052

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020020741-1A BR112020020741A2 (pt) 2018-04-10 2019-04-10 Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.

Country Status (10)

Country Link
US (1) US12024561B2 (https=)
EP (1) EP3773695A4 (https=)
JP (1) JP2021521168A (https=)
CN (1) CN112243379A (https=)
AU (1) AU2019251452A1 (https=)
BR (1) BR112020020741A2 (https=)
CO (1) CO2020013545A2 (https=)
SG (1) SG11202009872YA (https=)
WO (1) WO2019198099A1 (https=)
ZA (1) ZA202006262B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2358763C2 (ru) * 2003-02-10 2009-06-20 Элан Фармасьютикалз, Инк. Композиции иммуноглобулина и способ их получения
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
AR076640A1 (es) * 2009-03-06 2011-06-29 Genentech Inc Formulacion con anticuerpo. metodo para estabilizar anticuerpo. articulo de manufactura
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) * 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
AU2019251453A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy’S Laboratories Limited Stable formulations of therapeutic antibody
US12030948B2 (en) * 2018-04-10 2024-07-09 Dr. Reddy's Laboratories Limited Antibody formulation
US20220267449A1 (en) * 2019-06-10 2022-08-25 Takeda Pharmaceutical Company Limited METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY
AU2020290999A1 (en) * 2019-06-10 2022-02-03 Takeda Pharmaceutical Company Limited Antibody purification methods and compositions thereof

Also Published As

Publication number Publication date
SG11202009872YA (en) 2020-11-27
EP3773695A4 (en) 2021-12-22
CO2020013545A2 (es) 2021-01-18
EP3773695A1 (en) 2021-02-17
AU2019251452A1 (en) 2020-11-26
JP2021521168A (ja) 2021-08-26
ZA202006262B (en) 2023-01-25
US12024561B2 (en) 2024-07-02
AU2019251452A2 (en) 2020-12-03
WO2019198099A1 (en) 2019-10-17
CN112243379A (zh) 2021-01-19
US20210253714A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
BR112020020707A2 (pt) Formulação farmacêutica estável de um anticorpo alfa4beta7
BR112020020703A2 (pt) Formulações farmacêuticas estáveis de um anticorpo e do anticorpo ¿lfa4¿eta7 .
JP2021178862A (ja) タンパク質製剤
US20170106090A1 (en) Liquid pharmaceutical composition of adalimumab
EP4243859A1 (en) Stable aqueous high concentration formulation of integrin antibody
US20190284282A1 (en) Stable pharmaceutical composition
BR112019021723A2 (pt) formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
AU2020364436A1 (en) Stable formulation of integrin antibody
WO2022123603A1 (en) Stable aqueous buffer free formulation of an integrin antibody
BR112020020741A2 (pt) Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.
WO2025041000A1 (en) STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY
WO2023037384A1 (en) Formulations of immune check point inhibitors or like
WO2024023843A1 (en) A pharmaceutical formulation of a therapeuticantibody and preparations thereof

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2770 DE 06-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.